Across TCGA pan-cancer cohorts, ACTE1P Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ACTE1P data layer compared with 20 for mass-spec protein.
The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher ACTE1P Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ACTE1P expression acts as an unfavorable survival marker.
CESC are the cancer types where ACTE1P Mutation most reproducibly stratifies survival.